New Therapeutic Strategies for Adult Patients With Persistent and Chronic Immune Thrombocytopenia

Choosing treatment for patients with persistent or chronic ITP is incredibly complex with many factors involved. Take this opportunity to deepen your understanding of current and evolving best practices for the treatment of patients with ITP that has not responded well to initial therapy. 

Share

Program Content

No activities added yet

Supporters

Supported by educational grants from

Dova Pharmaceuticals

Novartis Pharmaceuticals Corporation